The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

[1]  Rajagopal N. Aravalli,et al.  Molecular mechanisms of hepatocellular carcinoma , 2008, Hepatology.

[2]  Zhao-You Tang,et al.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. El‐Serag,et al.  Oral contraception and the risk of hepatocellular carcinoma. , 2007, Journal of hepatology.

[4]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[6]  David B Seligson,et al.  Prognostic relevance of the mTOR pathway in renal cell carcinoma , 2007, Cancer.

[7]  Ronald A. DePinho,et al.  Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.

[8]  C. Wittekind,et al.  Pitfalls in der Klassifikation von Lebertumoren , 2006, Der Pathologe.

[9]  Frederick Y. Wu,et al.  Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. , 2006, Cancer research.

[10]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[11]  H. Blum,et al.  Hepatocellular carcinoma: therapy and prevention. , 2005, World journal of gastroenterology.

[12]  B. Law,et al.  Rapamycin: an anti-cancer immunosuppressant? , 2005, Critical reviews in oncology/hematology.

[13]  A. Tamakoshi,et al.  Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan , 2005, British Journal of Cancer.

[14]  David M Sabatini,et al.  An expanding role for mTOR in cancer. , 2005, Trends in molecular medicine.

[15]  M. Hall,et al.  The expanding TOR signaling network. , 2005, Current opinion in cell biology.

[16]  D. Hardie.  The AMP-activated protein kinase pathway – new players upstream and downstream , 2004, Journal of Cell Science.

[17]  Terry L. Smith,et al.  Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers , 2004, Clinical Cancer Research.

[18]  S. Chan,et al.  Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer , 2004, British Journal of Cancer.

[19]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[20]  K. Hasegawa,et al.  Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis. , 2004, Alcoholism, clinical and experimental research.

[21]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[22]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[23]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[24]  C. Lacombe,et al.  Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma , 2002, Oncogene.

[25]  Alfonso Bellacosa,et al.  Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.

[26]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[27]  S. Porru,et al.  Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. , 2002, American journal of epidemiology.

[28]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Kun-Liang Guan,et al.  Dysregulation of the TSC-mTOR pathway in human disease , 2004, Nature Genetics.